The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate whether GSK’s shingles vaccine, Shingrix (zoster vaccine recombinant ...